The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care.
Elisabetta PatornoMehdi NajafzadehAjinkya PawarJessica M FranklinAnouk Déruaz-LuyetKimberly G BrodoviczAdrian J Santiago OrtizLily G BessetteMartin KulldorffSebastian SchneeweissPublished in: Endocrinology, diabetes & metabolism (2019)
Baseline information from EMPRISE provided evidence of solid confounding control and adequate exposure accrual with expected powered analyses for the primary outcomes.